15-JUL-2024 6:10

LEUK ACCRUAL REPORT - Open and Recently Closed Studies

SWOG/
Support		 STUDY R
E
G		 O
P
E
N		 ARM ACCR.
GOAL		 TOTAL
REGS.		 REGS.
LAST
12
Month		 REGS.
LAST
6
Month		 REGS.
LAST
3
Month		 REGS.
LAST
30
DAYS		 REGS.
LAST
7
DAYS		 DATE OF
FIRST
REG.		 # of
ACT.
INSTs		 # of
CURR
IRBs
SWOG S1905-T-ALL/T-LBL, Rel/Ref, OBI-3424 1 Y 1 OBI-3424 8mg 64 5 0 0 0 0 0 02/08/2021 60 25
        2 OBI-3424 10mg   5 0 0 0 0 0      
        3 OBI-3424 12mg   5 2 1 1 0 0      
            15 2 1 1 0 0      
 
  S1925-CLL/SLL, Newly Dx HR, Early vs Delayed V+O 1 Y 1 Delayed V-O 247 38 12 6 3 2 0 03/02/2021 248 98
        2 Early V-O   71 23 17 8 3 0      
            109 35 23 11 5 0      
 
  MYELOMATCH-MSRP for the NCI myeloMATCH Clinical Trials 1 Y 1 Screening   5 5 5 5 5 0 06/18/2024 86 37
            5 5 5 5 5 0      
 
Yes A041701-AML, Age 60+, Conv Chemo +/- Uproleselan 0 E Total Registrations   52 0 0 0 0 0 06/10/2019 166 60
            52 0 0 0 0 0      
 
    1 E Total Registrations   38 0 0 0 0 0 06/10/2019    
            38 0 0 0 0 0      
 
  A042001-B-Cell ALL, Inotuzunab+chemo v Standard chemo 0 E Total Registrations   2 2 0 0 0 0 10/12/2023 126 44
            2 2 0 0 0 0      
 
    1 E Total Registrations   2 2 0 0 0 0 10/12/2023    
            2 2 0 0 0 0      
 
  EA9152-ALL, T/B-Cell, Venetoclax + Vincristine 0 E Total Registrations   4 1 1 0 0 0 01/17/2023 59 24
            4 1 1 0 0 0      
 
    1 E Total Registrations   3 1 1 0 0 0 01/17/2023    
            3 1 1 0 0 0      
 
  EA9213-T-ALL, dara-hyal for chemo refractory MRD 0 E Total Registrations   5 2 0 0 0 0 02/24/2023 54 16
            5 2 0 0 0 0      
 
    1 E Total Registrations   3 2 0 0 0 0 02/24/2023    
            3 2 0 0 0 0      
 
No A041501-B-Cell ALL, Frontline Tx +/- Intuzumab Ozo 0 E Total Registrations   71 0 0 0 0 0 11/09/2018 230 84
            71 0 0 0 0 0      
 
    1 E Total Registrations   57 0 0 0 0 0 11/09/2018    
            57 0 0 0 0 0      
 
    2 E Total Registrations   44 0 0 0 0 0 11/09/2018    
            44 0 0 0 0 0      
 
  A041703-ALL, Newly Dx, Inotuzumab Ozogamicin + Blinat 0 E Total Registrations   11 1 0 0 0 0 08/13/2020 136 54
            11 1 0 0 0 0      
 
    1 E Total Registrations   5 1 0 0 0 0 08/13/2020    
            5 1 0 0 0 0      
 
  EA9171-CML, Anti-PD-1 Pembrolizumab + TKIs 0 E Total Registrations   4 2 1 0 0 0 02/18/2020 91 39
            4 2 1 0 0 0      
 
    1 E Total Registrations   4 2 1 0 0 0 02/18/2020    
            4 2 1 0 0 0      
 
    2 E Total Registrations   1 0 0 0 0 0 02/18/2020    
            1 0 0 0 0 0      
 
  EA9181-ALL, BCR-ABL+, Steroids+TKI+CT/Blinatumomab 0 E Total Registrations   41 7 6 2 1 0 02/19/2021 176 59
            41 7 6 2 1 0      
 
    1 E Total Registrations   34 5 4 1 0 0 02/19/2021    
            34 5 4 1 0 0      
 
    2 E Total Registrations   30 4 3 2 1 0 02/19/2021    
            30 4 3 2 1 0      
 

15-JUL-2024 6:10

LEUK Open Studies with No Registrations

Study Registration/Phase Open Date # of
ACT.
INSTs		 # of
CURR
IRBs
EA9181 ALL, BCR-ABL+, Steroids+TKI+CT/Blinatumomab 3 Randomization 14-Oct-20 176 59
MM1YA-S01 AML, High Risk, Age <60, 7+3 vs experimental 1 Randomization 16-May-24 47 21
MYELOMATCH MSRP for the NCI myeloMATCH Clinical Trials 2 Re-screening 16-May-24 86 37
  3 Re-screening 16-May-24 86 37
  4 Re-screening 16-May-24 86 37